SCHEMBL9890734

SCHEMBL9890734

NC(=O)Cc1ccccc1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.49
FFAR4 Q5NUL3 1/20 0.49
PSEN1 P49768 1/20 0.46
PSEN2 P49810 1/20 0.46
APH1B Q8WW43 1/20 0.46
NCSTN Q92542 1/20 0.46
APH1A Q96BI3 1/20 0.46
PSENEN Q9NZ42 1/20 0.46
ICMT O60725 3/20 0.44
KIF11 P52732 4/20 0.44
BACE1 P56817 1/20 0.43
KCNJ5 P48544 1/20 0.43
KCNJ3 P48549 1/20 0.43
CYP2C19 P33261 1/20 0.43
GAA P10253 1/20 0.42
TACR1 P25103 2/20 0.40
PTGDR2 Q9Y5Y4 2/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890739 0.86 ICMT (0.52) ICMTTACR1RXRARXRBRXRG
SCHEMBL3729702 0.86 PSEN1 (0.57) FFAR1FFAR4PSEN1PSEN2APH1B
SCHEMBL2391627 0.84 RORB (0.51) ICMTKIF11
Trifluoroacetic Acid SCHEMBL27625600 0.83 KMT2A (0.47) FFAR1FFAR4CYP2C19TACR1
SCHEMBL2392196 0.82 PTGDR2 (0.46) FFAR1FFAR4ICMTCYP2C19PTGDR2
SCHEMBL9892688 0.82 PTGDR2 (0.53) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL9892691 0.82 PTGDR2 (0.50) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL9295643 0.81 TACR1 (0.51) FFAR1FFAR4PSEN1PSEN2APH1B
SCHEMBL2392176 0.81 RXRA (0.49) ICMTTACR1RXRARXRBRXRG
SCHEMBL1547038 0.81 KMT2A (0.56) FFAR1FFAR4CYP2C19PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 FFAR1 223/4885FFAR4 621/4885PSEN1 2126/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 FFAR1 223/4885FFAR4 621/4885PSEN1 2126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.